NA
GRCL

NewEdge Advisors’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

NewEdge Advisors’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-227
Closed -$865 – 3692
2023
Q2 		$865 Buy
+227
New +$636 ﹤0.01% 3266

Other funds holding GRCL

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

NewEdge Advisors's GRCL Position: Q3 2023 in Review

NewEdge Advisors sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q3 2023, closing a stake of 227 shares — an estimated $865 sold.

NewEdge Advisors first reported a position in GRCL in Q2 2023 and held it in 1 quarter. The position peaked at $865 in Q2 2023. 45 funds tracked by Wall St. Rank hold GRCL as of Q3 2023.

  • NewEdge Advisors reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q3 2023 after selling out during the quarter.
  • NewEdge Advisors sold 227 Gracell Biotechnologies Inc. American Depositary Shares shares in Q3 2023, an estimated $865.
  • NewEdge Advisors first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q2 2023 and held it in 1 quarter.
  • NewEdge Advisors's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $865 in Q2 2023.
  • 45 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q3 2023.

Based on NewEdge Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.